LC
HRTX icon

Lindbrook Capital’s Heron Therapeutics HRTX Stock Holding History

Lindbrook Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$56 – 2865
2024
Q2 		$56 Buy
+16
New +$49 ﹤0.01% 2729
2023
Q1 		– Sell
-588
Closed -$1.47K – 2837
2022
Q4 		$1.47K Buy
588
+519
+752% +$1.67K ﹤0.01% 2365
2022
Q3 		$0 Sell
69
-4
-5% -$16 ﹤0.01% 2742
2022
Q2 		$0 Buy
+73
New +$293 ﹤0.01% 2595
2020
Q3 		– Sell
-798
Closed -$12K – 1789
2020
Q2 		$12K Buy
+798
New +$13.1K ﹤0.01% 772
2020
Q1 		– Sell
-500
Closed -$12K – 1754
2019
Q4 		$12K Buy
+500
New +$11.1K ﹤0.01% 877
2019
Q3 		– Sell
-2,000
Closed -$37K – 1474
2019
Q2 		$37K Buy
+2,000
New +$40K 0.01% 506

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's HRTX Position: Q3 2024 in Review

Lindbrook Capital sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 16 shares — an estimated $56 sold.

Lindbrook Capital first reported a position in HRTX in Q2 2019 and held it in 7 quarters. The position peaked at $37K in Q2 2019. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Lindbrook Capital reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lindbrook Capital sold 16 Heron Therapeutics shares in Q3 2024, an estimated $56.
  • Lindbrook Capital first reported a position in Heron Therapeutics in Q2 2019 and held it in 7 quarters.
  • Lindbrook Capital's Heron Therapeutics position peaked at $37K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.